Jeanmarie Guenot has a wealth of experience in the biotechnology and the pharmaceutical industry. Being a graduate from the University of California and the University of Pennsylvania, where she earned her Ph.D. and Master’s in business administration respectively, it is evident that she is well versed with knowledge and skills in business and pharmaceuticals.
She has served various companies both private and public, in pharmaceutical R&D, business development, venture capital, project and alliance management as well as corporate and commercial management. She has significant interest and expertise in rebuilding and building firms, and she is presently the chief executive officer and president of the prominent Amphivena Therapeutics, Inc. This company develops innovative and high quality bifunctional antibody therapies meant for hematologic malignancies.
Before embarking to her current role, Jeanmarie Guenot established SKA Ocular, a company she built and ran by herself. This firm was a startup ophthalmic firm incubator that specialized in therapeutics for ocular inflammation, macular degeneration and glaucoma as well as dry AMD among others. She was also a business advisor for the well-known Hoffman La Roche located in Shanghai and Basel. Being a committed individual, she also served as the vice-president at PDL Biopharma. Here her main area of focus was in licensing, commercial product portfolios, mergers and acquisitions and alliance management for R$D.
She began her lifelong career in business at Atlas Ventures. Here she was able to build life science firms and manage venture capital investments. She also started her scientific career in preclinical R$ D as a principal scientist. She was very instrumental since she discovered and developed various drugs for inflammation, metabolic diseases, oncology and autoimmune diseases. She trained in medicinal and physical chemistry, with a main focus in semi-practical and quantum mechanical methods for protein structure prediction, molecular dynamics, drug design and NMR and X-ray refinement.
This company is located in San Francisco, California. Under the leadership of Dr. Guenot, Amphivena managed to raise $14miliion in 2013 in a series A contribution led by the prominent MPM Capital Amphivena. Furthermore, the firm entered an important agreement with Janssen Biotech. This agreement granted Janssen an exclusive right to acquire Amphivena following the IND approval.